DBD(DBD)
DBD
$66.00—
NYSE
$66.00—
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2026E | FY2027E |
|---|---|---|
| Revenue Avg | $3.89B | $4.02B |
| Low | $3.88B | $4.00B |
| High | $3.91B | $4.05B |
| EBITDA Avg | $540M | $587M |
| Low | $537M | $570M |
| High | $543M | $647M |
| EBIT Avg | $431M | $491M |
| Low | $428M | $474M |
| High | $434M | $551M |
| Net Income Avg | $200M | $245M |
| Low | $198M | $232M |
| High | $202M | $290M |
| EPS Avg | $5.37 | $7.02 |
| Low | $5.31 | $6.24 |
| High | $5.43 | $7.79 |
| Analysts (Rev / EPS) | 2 / 2 | 2 / 2 |
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 |
|---|---|---|---|---|---|---|
| Revenue Avg | $972M | $1.12B | $914M | $964M | $995M | $1.13B |
| Low | $962M | $1.11B | $907M | $956M | $986M | $1.12B |
| High | $981M | $1.12B | $920M | $970M | $1.00B | $1.14B |
| EBITDA Avg | $114M | $161M | $105M | $125M | $134M | $176M |
| Low | $109M | $154M | $105M | $124M | $133M | $174M |
| High | $119M | $167M | $106M | $126M | $134M | $177M |
| EBIT Avg | $85M | $132M | $78M | $98M | $108M | $151M |
| Low | $80M | $126M | $77M | $98M | $107M | $149M |
| High | $90M | $139M | $79M | $99M | $109M | $152M |
| Net Income Avg | $46M | $82M | $41M | $56M | $64M | $95M |
| Low | $42M | $77M | $41M | $56M | $63M | $94M |
| High | $50M | $87M | $42M | $57M | $64M | $96M |
| EPS Avg | $1.31 | $2.32 | $1.17 | $1.60 | $1.80 | $2.71 |
| Low | $1.20 | $2.18 | $1.16 | $1.58 | $1.79 | $2.68 |
| High | $1.41 | $2.46 | $1.18 | $1.61 | $1.82 | $2.73 |
| Analysts (Rev / EPS) | 2 / 2 | 2 / 2 | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 |